ClinicalTrials.gg
CompletedNCT01405963Updated Oct 17, 2022Results posted

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

A Phase 1 interventional study of Placebo and Tezepelumab in Asthma, sponsored by Amgen. Completed at 5 sites in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
22nd of 28
31 · median 121
Started
2011
the only one that year
Phase 1
4 of 28
none open now
Registered
1st of 28
by date
Lead sponsor
1 of 28
Amgen

Among the 28 studies testing tezepelumab in Asthma, this one is the 22nd largest by enrollment, is the only one that started in 2011, is one of 4 in phase 1, and was the 1st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Amgen
  • AMG 157
  • Asthma
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with history of mild atopic asthma between 18 and 60 years-of-age
  • (BMI) between 18 and 35 kg/m\^2
  • Normal or clinically acceptable physical examination (PE), clinical laboratory values, and (ECG); clinically acceptable PE includes history of mild atopic asthma
  • Used only inhaled short-acting β2-agonists infrequently to treat asthma
  • No current exposure to allergens to which subject experiences asthmatic responses
  • No other lung disease, exacerbations of asthma or lower respiratory tract infections for at least 6 weeks prior to screening
  • Positive skin prick test to common aeroallergens at screening
  • Additional inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • History or evidence of a disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
  • History or current medical conditions that are for methacholine challenge, such as myocardial infarction or stroke within previous 3 months, known cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm
  • Evidence of active or suspected bacterial, viral, fungal or parasitic infections within past 6 weeks
  • Subject has know type I/II diabetes
  • History of residential exposure to tuberculosis or has a positive purified protein derivative (PPD) or QuantiFERON test within 4 weeks before randomization
  • Subject who has history of of any type within 5 years prior to enrollment
  • Subjects tested positive for drugs/alcohol or nicotine use at screening
  • Subjects tested positive for (HIV), or
  • Additional exclusion criteria apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo to tezepelumab administered by intravenous infusion on study days 1, 29, and 57.

    Drug: Placebo

  • Experimental
    Tezepelumab 700 mg

    Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.

    Biological: Tezepelumab

Interventions

  • DrugPlacebo

    Administered in a 1-hour intravenous infusion

  • BiologicalTezepelumab

    Administered in a 1-hour intravenous infusion

    Also known as: AMG 157, Tezspire

06

What researchers measure

Primary outcomes

  1. Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction (measured by a fall in FEV1). FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). The percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during late (3-7 hour) asthmatic response time frame.

    Time frame: Days 42 and 84 at pre-allergen challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge

  2. Time-Adjusted Area Under the Curve for the Percent Decrease From Pre-Allergen Challenge in Forced Expiratory Volume in 1 Second (FEV1) From 3 to 7 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR). The percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

    Time frame: Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge

Secondary outcomes

  1. Number of Participants With Adverse Events

    A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life-threatening, * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event. The severity of each adverse event was graded by the Investigator as mild, moderate, severe, life-threatening, or fatal according to the Common Terminology Criteria for Adverse Events (Version 4).

    Time frame: Up to 169 days

  2. Number of Participants With Grade ≥ 3 Laboratory Values

    Laboratory toxicities were graded according to the Common Terminology Criteria for Adverse Events (Version 4) on a scale from grade 1 (mild) to 5 (death).

    Time frame: Up to 169 days

  3. Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment

    All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

    Time frame: Days 29, 57, 85, 113, and 169

  4. Maximum Percentage Decrease in FEV1 From 0 to 2 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during early (0-2 hour) asthmatic response time frame.

    Time frame: Days 42 and 84 at pre-allergen challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge

  5. Time-Adjusted AUC for the Percent Decrease From Pre-Allergen Challenge in FEV1 From 0 to 2 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The percent change in FEV1 from pre-allergen challenge was calculated to each time point between 0 to 2 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

    Time frame: Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge

  6. Minimum FEV1 From 0 to 2 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The minimum FEV1 post onset of the allergen challenge for EAR is defined as the smallest value of FEV1 measured during 0 to 2 hours post allergen challenge.

    Time frame: Days 42 and 84 at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge

  7. Time-Adjusted AUC for FEV1 From 0 to 2 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The area under the curve for the FEV1 between 0 to 2 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

    Time frame: Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge

  8. Minimum FEV1 From 3 to 7 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR). The minimum FEV1 post allergen challenge for LAR is defined as the smallest value of FEV1 measured during 3 to 7 hours post allergen challenge.

    Time frame: Days 42 and 84 at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge

  9. Time-Adjusted AUC for FEV1 From 3 to 7 Hours Post Allergen Challenge

    Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). The area under the curve for the FEV1 between 3 to 7 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

    Time frame: Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge.

  10. Maximum Observed Serum Concentration (Cmax) of Tezepelumab

    The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

  11. Time of Maximum Observed Concentration (Tmax) of Tezepelumab

    The PK parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

  12. Minimum Observed Serum Concentration (Cmin) of Tezepelumab

    The PK parameter Cmin was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

  13. Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab

    The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.

  14. Accumulation Ratio Based on AUCtau

    Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.

  15. Accumulation Ratio Based on Cmax

    Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose.

    Time frame: First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

  16. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab

    The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

  17. Terminal Half-life (t1/2z) of Tezepelumab After Last Dose

    The PK parameter t1/2,z was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.

07

Results

Posted Oct 17, 2022

Participant flow

This proof-of-concept, randomized, double-blind, placebo-controlled study was conducted at 5 centers in Canada.

Participant flow — Overall Study
MilestonePlaceboTezepelumab 700 mg
Started1516
Completed1314
Not completed22
Withdrew: Moved away20
Withdrew: Adverse event01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryMaximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction (measured by a fall in FEV1). FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). The percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during late (3-7 hour) asthmatic response time frame.

Time frame:
Days 42 and 84 at pre-allergen challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge
Reported as:
Mean · percent change
Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge
percent changePlaceboTezepelumab 700 mg
Day 42-20.645 ± 11.554-16.949 ± 14.209
Day 84-19.366 ± 14.686-12.064 ± 9.131
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.09 · Treatment difference: 7.65 · 95% CI -1.30 to 16.60Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.02 · Treatment difference: 9.91 · 95% CI 1.59 to 18.23Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
PrimaryTime-Adjusted Area Under the Curve for the Percent Decrease From Pre-Allergen Challenge in Forced Expiratory Volume in 1 Second (FEV1) From 3 to 7 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR). The percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

Time frame:
Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge
Reported as:
Mean · percent change
Time-Adjusted Area Under the Curve for the Percent Decrease From Pre-Allergen Challenge in Forced Expiratory Volume in 1 Second (FEV1) From 3 to 7 Hours Post Allergen Challenge
percent changePlaceboTezepelumab 700 mg
Day 4212.062 ± 8.2319.321 ± 10.787
Day 8411.864 ± 9.4827.569 ± 7.069
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.11 · Treatment difference: -4.35 · 95% CI -9.80 to 1.10Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.07 · Treatment difference: -4.66 · 95% CI -9.71 to 0.39Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryNumber of Participants With Adverse Events

A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life-threatening, * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event. The severity of each adverse event was graded by the Investigator as mild, moderate, severe, life-threatening, or fatal according to the Common Terminology Criteria for Adverse Events (Version 4).

Time frame:
Up to 169 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboTezepelumab 700 mg
Any adverse event1215
Serious adverse event00
Leading to discontinuation of study drug02
Leading to discontinuation from study01
Severe adverse events10
Life-threatening adverse events00
Fatal adverse events00
Treatment-related adverse events34
SecondaryNumber of Participants With Grade ≥ 3 Laboratory Values

Laboratory toxicities were graded according to the Common Terminology Criteria for Adverse Events (Version 4) on a scale from grade 1 (mild) to 5 (death).

Time frame:
Up to 169 days
Reported as:
Count of participants · Participants
Number of Participants With Grade ≥ 3 Laboratory Values
ParticipantsPlaceboTezepelumab 700 mg
Any Grade ≥ 3 Laboratory Toxicity22
Increased creatine kinase21
Decreased lymphocytes01
SecondaryNumber of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment

All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

Time frame:
Days 29, 57, 85, 113, and 169
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment
ParticipantsPlaceboTezepelumab 700 mg
Anti-tezepelumab binding antibodies10
Anti-tezepelumab neutralizing antibodies00
SecondaryMaximum Percentage Decrease in FEV1 From 0 to 2 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during early (0-2 hour) asthmatic response time frame.

Time frame:
Days 42 and 84 at pre-allergen challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge
Reported as:
Mean · percent change
Maximum Percentage Decrease in FEV1 From 0 to 2 Hours Post Allergen Challenge
percent changePlaceboTezepelumab 700 mg
Day 42-33.296 ± 10.084-22.501 ± 15.001
Day 84-33.160 ± 15.280-20.990 ± 13.393
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.05 · Treatment difference: 8.57 · 95% CI 0.01 to 17.13Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.06 · Treatment difference: 10.27 · 95% CI -0.46 to 21.00Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryTime-Adjusted AUC for the Percent Decrease From Pre-Allergen Challenge in FEV1 From 0 to 2 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The percent change in FEV1 from pre-allergen challenge was calculated to each time point between 0 to 2 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

Time frame:
Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge
Reported as:
Mean · percent change
Time-Adjusted AUC for the Percent Decrease From Pre-Allergen Challenge in FEV1 From 0 to 2 Hours Post Allergen Challenge
percent changePlaceboTezepelumab 700 mg
Day 4218.592 ± 8.43211.284 ± 11.509
Day 8420.179 ± 10.97311.297 ± 10.708
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.03 · Treatment difference: -6.08 · 95% CI -11.56 to -0.60Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.03 · Treatment difference: -7.44 · 95% CI -14.22 to -0.66Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryMinimum FEV1 From 0 to 2 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The minimum FEV1 post onset of the allergen challenge for EAR is defined as the smallest value of FEV1 measured during 0 to 2 hours post allergen challenge.

Time frame:
Days 42 and 84 at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge
Reported as:
Mean · liters
Minimum FEV1 From 0 to 2 Hours Post Allergen Challenge
litersPlaceboTezepelumab 700 mg
Day 422.211 ± 0.5892.682 ± 0.839
Day 842.184 ± 0.7202.774 ± 0.826
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.05 · Treatment difference: 0.33 · 95% CI -0.01 to 0.68Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.08 · Treatment difference: 0.39 · 95% CI -0.06 to 0.84Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryTime-Adjusted AUC for FEV1 From 0 to 2 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR). The area under the curve for the FEV1 between 0 to 2 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

Time frame:
Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge
Reported as:
Mean · liters
Time-Adjusted AUC for FEV1 From 0 to 2 Hours Post Allergen Challenge
litersPlaceboTezepelumab 700 mg
Day 422.709 ± 0.6953.076 ± 0.844
Day 842.607 ± 0.6813.120 ± 0.856
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.03 · Treatment difference: 0.28 · 95% CI 0.03 to 0.53Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.06 · Treatment difference: 0.33 · 95% CI -0.01 to 0.66Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryMinimum FEV1 From 3 to 7 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR). The minimum FEV1 post allergen challenge for LAR is defined as the smallest value of FEV1 measured during 3 to 7 hours post allergen challenge.

Time frame:
Days 42 and 84 at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge
Reported as:
Mean · liters
Minimum FEV1 From 3 to 7 Hours Post Allergen Challenge
litersPlaceboTezepelumab 700 mg
Day 422.659 ± 0.7782.943 ± 1.036
Day 842.627 ± 0.8643.097 ± 0.827
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.01 · Treatment difference: 0.41 · 95% CI 0.12 to 0.70Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.01 · Treatment difference: 0.42 · 95% CI 0.11 to 0.72Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryTime-Adjusted AUC for FEV1 From 3 to 7 Hours Post Allergen Challenge

Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). The area under the curve for the FEV1 between 3 to 7 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.

Time frame:
Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge.
Reported as:
Mean · liters
Time-Adjusted AUC for FEV1 From 3 to 7 Hours Post Allergen Challenge
litersPlaceboTezepelumab 700 mg
Day 422.940 ± 0.7813.188 ± 0.994
Day 842.853 ± 0.7803.252 ± 0.831
Statistical analysis
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.02 · Treatment difference: 0.24 · 95% CI 0.04 to 0.45Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
  • Placebo vs Tezepelumab 700 mg · ANCOVA · p = 0.15 · Treatment difference: 0.18 · 95% CI -0.07 to 0.44Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA.
SecondaryMaximum Observed Serum Concentration (Cmax) of Tezepelumab

The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration (Cmax) of Tezepelumab
μg/mLTezepelumab 700 mg
First dose262 ± 73
Last dose325 ± 81
SecondaryTime of Maximum Observed Concentration (Tmax) of Tezepelumab

The PK parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Median · hours
Time of Maximum Observed Concentration (Tmax) of Tezepelumab
hoursTezepelumab 700 mg
First dose2.1 (1.0 to 5.2)
Last dose2.0 (1.1 to 5.0)
SecondaryMinimum Observed Serum Concentration (Cmin) of Tezepelumab

The PK parameter Cmin was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Mean · μg/mL
Minimum Observed Serum Concentration (Cmin) of Tezepelumab
μg/mLTezepelumab 700 mg
First dose60.7 ± 20.8
Last dose17.7 ± 13.4
SecondaryArea Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab

The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab
day*μg/mLTezepelumab 700 mg
First dose2730 ± 700
Last dose4420 ± 1250
SecondaryAccumulation Ratio Based on AUCtau

Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.
Reported as:
Mean · ratio
Accumulation Ratio Based on AUCtau
ratioTezepelumab 700 mg
Accumulation Ratio Based on AUCtau1.64 ± 0.25
SecondaryAccumulation Ratio Based on Cmax

Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose.

Time frame:
First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Mean · ratio
Accumulation Ratio Based on Cmax
ratioTezepelumab 700 mg
Accumulation Ratio Based on Cmax1.31 ± 0.25
SecondaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab
day*μg/mLTezepelumab 700 mg
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab8620 ± 2440
SecondaryTerminal Half-life (t1/2z) of Tezepelumab After Last Dose

The PK parameter t1/2,z was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.
Reported as:
Mean · days
Terminal Half-life (t1/2z) of Tezepelumab After Last Dose
daysTezepelumab 700 mg
Terminal Half-life (t1/2z) of Tezepelumab After Last Dose28.0 ± 4.2

Adverse events

Collected over 169 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/15 (0%)12/15 (80%)
Tezepelumab 700 mg—0/16 (0%)15/16 (93.8%)
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlaceboTezepelumab 700 mg
NasopharyngitisInfections and infestations4/154/16
HeadacheNervous system disorders3/152/16
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/153/16
Iron deficiency anaemiaBlood and lymphatic system disorders2/150/16
Abdominal painGastrointestinal disorders2/151/16
DiarrhoeaGastrointestinal disorders2/150/16
Lower respiratory tract infectionInfections and infestations2/150/16
MyalgiaMusculoskeletal and connective tissue disorders0/152/16
AsthmaRespiratory, thoracic and mediastinal disorders1/152/16
Ear painEar and labyrinth disorders1/150/16

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTezepelumab 700 mgTotal
Mean31.5 ± 11.230.8 ± 10.931.1 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTezepelumab 700 mgTotal
Female111021
Male4610
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTezepelumab 700 mgTotal
American Indian or Alaska Native000
Asian123
Black or African American000
Native Hawaiian or Other Pacific Islander000
White131427
Other101
Forced Expiratory Volume in 1 Second (FEV1)
Forced Expiratory Volume in 1 Second (FEV1)(liters)PlaceboTezepelumab 700 mgTotal
Mean3.335 ± 0.7533.358 ± 0.8653.346 ± 0.799
08

Study locations

5 sites
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Research Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
09

References and documents

Publications

  • Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C, Gorski KS, Smith L, Bautista E, Comeau MR, Leigh R, Parnes JR. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014 May 29;370(22):2102-10. doi: 10.1056/NEJMoa1402895. Epub 2014 May 20. PubMed 24846652 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Apr 2013, 17 months.

Results were first posted in Oct 2022, 9 years 6 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 17 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2011
First posted
Jul 29, 2011
StartActual
Oct 31, 2011
Primary completionActual
Apr 5, 2013
CompletionActual
Apr 5, 2013
Results first posted
Oct 17, 2022
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01405963
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 29, 2011
Start date
Oct 31, 2011
Primary completion
Apr 5, 2013
Completion
Apr 5, 2013
Results posted
Oct 17, 2022
Last update
Oct 17, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion